UNCY shares tumbled -34.22% on Tuesday, falling from a previous close of $7.13 to $4.69, after the FDA issued a second Complete Response Letter for its kidney disease drug candidate oxylanthanum carbonate. The selloff ignited in premarket trading and intensified during the regular session, with intraday losses briefly exceeding -46% before a partial recovery into the close.

NVCT shares are trading approximately 22% lower in premarket on June 30, 2026, following the overnight pricing of a deeply discounted equity offering. The primary catalyst is Nuvectis Pharma's pricing of a $100 million underwritten public offering of 5 million shares at $20.00 each — a roughly 30% discount to the prior session's closing price of $28.53.

OMER shares are plunging approximately 26% in premarket trading on Friday, June 26, 2026, from a prior close of $10.72 to around $7.93. The primary catalyst is a negative opinion issued by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP), which rejected the marketing authorization application for narsoplimab (YARTEMLEA) in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in Europe.

SPRY shares plunged approximately 26% in premarket trading on June 25, 2026, falling from the prior session's close of $10.54 to roughly $7.80. The primary catalyst was a late Wednesday commercial update confirming no new commercial formulary additions for neffy (epinephrine nasal spray) in the July 1, 2026 payer coverage cycle — a significant miss against market expectations.

SYRE shares are down approximately 10.87% in premarket trading on Wednesday, June 24, 2026, extending a decline that began in the prior regular session. The selloff follows a period of sharp appreciation driven by positive clinical trial data, with profit-taking accelerating as the stock hit multi-month highs and insider lock-up expirations from the April 2026 equity offering came into focus.

APGE surged +46.75% to $132.63 during regular market hours from a prior close of $90.38. Primary catalyst was AbbVie’s $10.9 billion cash acquisition announcement.

Shares of Definium Therapeutics (DFTX) surged approximately 55% in premarket trading on Monday, June 22, 2026, following a landmark clinical data readout. The primary catalyst is a positive Phase 3 Emerge trial result for DT120 ODT — an LSD-based orally disintegrating tablet — which met its primary endpoint with high statistical significance (p<0.0001) in treating major depressive disorder.

Shares of Apogee Therapeutics (APGE) surged approximately 46% in premarket trading on Monday, June 22, 2026, following a confirmed acquisition announcement. AbbVie Inc. (ABBV) announced it will acquire Apogee Therapeutics for $10.9 billion in an all-cash transaction, offering $135.11 per share.

LIXT shares surged approximately 44.4% over the last 30 days, climbing from $5.27 on May 19, 2026, to $7.61 as of June 18, 2026, driven by a transformative strategic pivot and acquisition news. The company announced a definitive agreement to acquire NOMAD Transportable Power Systems, a provider of mobile, utility-grade battery energy storage systems, and plans to rename itself NOMAD Power Solutions.

SLBT shares declined approximately 19.6% over the past 30 days, closing at $6.28 on June 17, 2026, compared to $7.81 on May 18, 2026. The stock has experienced extreme volatility following its June 15 Nasdaq debut after completing a SPAC merger with Horizon Space Acquisition II Corp.

Legend Biotech shares are down approximately 11% in premarket trading on June 18, 2026, after closing the prior session at $33.52 on June 17. The primary catalyst is the company's announced pricing of a $226 million underwritten public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 per ADS — a significant discount to the prior closing price.

RGNX shares surged 22.80% to close at $8.51 on June 17, 2026, up from the prior session's close of $6.93, marking the stock's strongest single-day gain since the May 14 selloff. Primary catalyst: Anticipation of the imminent $100 million AbbVie milestone payment , triggered upon first patient dosing in the Phase IIb/III NAAVIGATE diabetic retinopathy study, which management guided would occur in Q2 2026 — a quarter that ends in just 13 days.

QURE shares are surging approximately 84% in Wednesday's premarket session, trading near $49.79 versus a prior closing price of $26.99. The primary catalyst is a major FDA regulatory breakthrough: the agency confirmed during a recent Type B meeting that uniQure's existing 3-year Phase I/II clinical data for AMT-130 can serve as the primary basis for a Biologics License Application (BLA) under an accelerated approval pathway.

VRXA shares plummeted 56.02% to $9.35 during Tuesday's session, down from the previous close of $21.26. The primary driver is extreme post-SPAC volatility tied to an exceptionally small public float following the company's recent business combination.

NMRA shares are plunging approximately 51% in premarket trading on Monday, June 15, 2026, from a prior close of $1.78 to an indicated price near $0.87. Primary catalyst: Neumora's KOASTAL-2 and KOASTAL-3 Phase 3 trials of navacaprant in major depressive disorder (MDD) both failed to achieve statistically significant improvements on primary and key secondary endpoints versus placebo.

NUVL shares surged approximately 38.83% in premarket trading on June 9, 2026, from a prior close of $88.49 to around $122.85. The primary catalyst is a definitive acquisition agreement: GlaxoSmithKline (GSK) announced it will acquire Nuvalent for $124 per share in an all-cash tender offer. The deal values Nuvalent at approximately $10.6 billion and represents a roughly 40% premium to Monday's closing price.

TNGX shares surged approximately 47.03% in premarket trading on June 8, 2026, to around $29.73 from Friday’s closing price of $20.22. The primary catalyst is the announcement of positive initial Phase 1/2 clinical trial results for the combination of vopimetostat and daraxonrasib in pancreatic ductal adenocarcinoma, demonstrating a 92% objective response rate.

MLYS shares fell sharply, declining approximately 14.61% from the prior session close of $28.85 to a latest available price of $24.635. No single company-specific catalyst such as earnings or major announcements appears to have triggered the move.

Greenwich LifeSciences, Inc. (GLSI) shares fell sharply, declining approximately 17.56% intraday.